Kyverna Therapeutics Shares Rise on Positive Trial Results

Kyverna Therapeutics shares are trading higher after the company reported positive topline data from its Phase 2 KYSA-8 trial, demonstrating significant clinical benefits of miv-cel in Stiff Person Syndrome.